Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)

NCT00770120 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT00770120
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00770120 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of mTOR Inhibitor, Everolimus (RAD001), in Malignant Pleural Mesothelioma (MPM)
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2008
Completion date
April 30, 2014
Enrollment
61 (actual)
Sites
129

Conditions

As the registry lists them; a condition with its own page is linked.

malignant mesothelioma